Table 2. Serum HE4 and CA125 concentrations in patients with endometriosis, endometrial, and ovarian cancer.
|
HE4 (pM)
|
CA125 (U ml−1)
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis | n | Mean | s.d. | Median | (range) | P-valuea | Mean | s.d. | Median | (range) | P-valuea |
| Controls | 66 | 40.5 | 10.3 | 38.6 | (27.0–80.7) | — | 8.9 | 6.2 | 6.7 | (2.2–31.2) | — |
| Endometriosis all | 129 | 45.5 | 13.4 | 43.5 | (15.2–111.0) | — | 35.8 | 36.0 | 25.3 | (0.8–182.0) | — |
| Stage 1 | 16 | 46.7 | 11.4 | 42.9 | (35.1–80.9) | 0.96192 | 15.6 | 9.8 | 11.5 | (5.1–44.4) | 0.34560 |
| Stage 2 | 17 | 44.9 | 13.1 | 43.9 | (28.7–72.0) | 0.99718 | 21.4 | 18.4 | 14.8 | (3.5–70.5) | 0.09637 |
| Stage 3 | 33 | 43.2 | 11.4 | 43.4 | (15.2–68.0) | — | 25.1 | 22.7 | 14.8 | (0.9–79.0) | — |
| Stage 3 w/o OvEndo | 9 | 43.9 | 10.1 | 43.8 | (32.6–61.9) | 0.99971 | 23.3 | 25.4 | 13.4 | (2.6–79.0) | 0.58802 |
| Stage 4 | 63 | 46.5 | 15.0 | 44.0 | (26.8–111.0) | — | 50.4 | 43.1 | 36.7 | (0.8–182.0) | — |
| Stage 4 w/o OvEndo | 18 | 43.5 | 12.1 | 40.9 | (27.4–64.5) | 0.99973 | 40.8 | 30.9 | 32.1 | (0.8–127.0) | 0.00001 |
| Ovarian endometriosis | 69 | 46.0 | 14.9 | 44.0 | (15.2–111.0) | 0.89441 | 44.3 | 42.1 | 33.7 | (0.9–182.0) | 0.00000 |
| Endometrial cancer | 16 | 99.2 | 76.4 | 73.3 | (26.5–330.5) | 0.00001 | 22.0 | 23.0 | 15.5 | (9.6–106.0) | 0.02915 |
| Ovarian cancer | 14 | 1125.4 | 2670.0 | 268.3 | (46.5–10250.0) | 0.00000 | 1117.1 | 1971.0 | 240.0 | (6.6–6890.0) | 0.00000 |
| 0.00000b | 0.00000b | ||||||||||
| Serous | 7 | 2031.1 | 3669.1 | 562.5 | (46.5–10250.0) | — | 1938.7 | 2588.7 | 341.0 | (28.9–6890.0) | — |
| Mucinous | 3 | 202.6 | 189.7 | 113.0 | (74.4–420.5) | — | 201.5 | 186.0 | 221.0 | (6.6–377.0) | — |
| Clear cell | 2 | 397.6 | 477.2 | 397.6 | (60.1–735.0) | — | 674.5 | 587.6 | 674.5 | (259.0–1090.0) | — |
| Endometrioid | 1 | 70.0 | — | 70.0 | — | — | 97.0 | — | 97.0 | — | — |
| Small cell | 1 | 64.1 | — | 64.1 | — | — | 17.8 | — | 17.8 | — | — |
a
Tukey's multiple comparisons of means, in comparison to the healthy controls.
b
Comparison to patients with ovarian endometriosis.